7/30/2019 abvd

1/4

Lymphoma group

This is a controlled document and therefore must not be changed or photocopiedABVD Authorised by Lymphoma lead

Dr. Chris Hatton

Date: August 2012

Published: September 2008Reviewed: May 2010

Amended: June 2011May & Aug 2012

Review: June 2013

Version3.4

1 of 4

ABVD

INDICATION

Hodgkin lymphoma. Please refer to the bleomycin supportive care document.

TREATMENT INTENT

Curative.

PRE-ASSESSMENT

1. Ensure histology is confirmed prior to administration of chemotherapy and document innotes.

2. Record stage of disease - CT scan (neck, chest, abdomen and pelvis) and/or PET-CT scan,presence or absence of B symptoms, clinical extent of disease.

3. Bone marrow aspirate and trephine if Stage IIB IV radiologically.

4. Pulmonary function tests before course one and as clinically indicated (see bleomycinsupportive care document).

5. Blood tests - FBC, ESR, DAT, U&Es, LDH, urate, calcium, magnesium, creatinine, LFTs,glucose, Igs, 2 microglobulin, Hep B&C, EBV, CMV, VZV, HIV 1+2 after consent.

6. Send a "group and save" sample to transfusion and inform patient and transfusion

laboratory that they will require irradiated blood products for all future transfusions.

Ensure card is attached to the patient's notes and copy given to the patient.7. Urine pregnancy test - before cycle 1 of each new chemotherapy course in women aged 12

55 years of age unless they have been sterilised or undergone a hysterectomy.

8. ECG +/- Echo - if clinically indicated.

9. Record performance status (WHO/ECOG).

10. Record height and weight.

11. Consent - ensure patient has received adequate verbal and written information regardingtheir disease, treatment and potential side effects. Document in medical notes all information

that has been given. Obtain written consent prior to treatment.

12. Fertility - it is very important the patient understands the potential risk of reduced fertility. All

patients should be offered fertility advice (see fertility guidelines).13. Hydration - in patients with bulky disease pre-hydrate with sodium chloride 0.9% 1 litre over

4-6 hours. For patients at high risk of tumour lysis, refer to the tumour lysis protocol.

14. Consider dental assessment / Advise dental check is carried out by patient's own dental

practitioner before treatment starts.

15. Treatment should be agreed in the relevant MDT.

For early stage disease, classify into favourable or unfavourable see treatment pathway.

7/30/2019 abvd

2/4

Lymphoma group

This is a controlled document and therefore must not be changed or photocopiedABVD Authorised by Lymphoma lead

Dr. Chris Hatton

Date: August 2012

Published: September 2008Reviewed: May 2010

Amended: June 2011May & Aug 2012

Review: June 2013

Version3.4

2 of 4

DRUG REGIMEN

Each 4 week cycle consists of:Day 1 DOXORUBICIN 25 mg/m2 iv bolus.

Day 1 VINBLASTINE** 6 mg/m2 iv infusion in 50 ml sodium chloride 0.9% over 10 minutes.

Day 1 DACARBAZINE 375 mg/m

2

iv infusion in 250-500 ml sodium chloride 0.9% over 1-2 hours.Day 1 BLEOMYCIN* 10,000 units/m2 in 100 ml sodium chloride 0.9% iv infusion over >1 hour.Day 15 DOXORUBICIN 25 mg/m2 iv bolus.

Day 15 VINBLASTINE** 6 mg/m2 iv infusion in 50 ml sodium chloride 0.9% over 10 minutes.Day 15 DACARBAZINE 375 mg/m2 iv infusion in 250-500 ml sodium chloride 0.9% over 1-2 hours.Day 15 BLEOMYCIN* 10,000 units/m2 in 100 ml sodium chloride 0.9% iv infusion over >1 hour.

NB: * Maximum of 6 courses (12 doses) of bleomycin may be given.** No 'ceiling' for vinblastine dosage in this protocol.

CYCLE FREQUENCY

Each course is given every 28 days (ABVD is administered on Day 1 and Day 15).

Treatment should be delivered on time irrespective of the neutrophil count. Patients should not normally be supported with G-CSF. Patients who are unwell should be deferred by one week. Aim to treat to complete response + 2 courses. Maximum of 8 courses. Bleomycin should be omitted from courses 7 and 8.

RESTAGING

Clinical assessment at least prior to each course and document in notes. Formal restaging including CT scan after 4, 6 and 8 courses as indicated. If performing PET-CT scan at end of treatment, wait 6 8 weeks after last course.

PET-CT scan after two courses is currently NOT recommended outside the context of aclinical trial.

DOSE MODIFICATIONS

If patient is on clinical trial, modify as per trial protocol.

All drugs will be given at full dose and on schedule with no dose delays or reduction forhaematological toxicity. Discuss with consultant patients who are unwell / admission withneutropenic sepsis/platelets 85

Dose

50% dose reduction75% dose reduction

omit

Discuss with consultant if renal

impairment severe

If AST 2-3 x normal, give 25% dose reductionIf AST >3 x ULN, give 50% dose reduction

Doxorubicin maximum cumulative dose (additive to other anthracyclines):450-550 mg/m2 (in normal cardiac function)400 mg/m2 (in patients with cardiac dysfunction or exposed to mediastinal irradiation).Consider dose reduction in the event of cardiac impairment.

7/30/2019 abvd

3/4

Lymphoma group

This is a controlled document and therefore must not be changed or photocopiedABVD Authorised by Lymphoma lead

Dr. Chris Hatton

Date: August 2012

Published: September 2008Reviewed: May 2010

Amended: June 2011May & Aug 2012

Review: June 2013

Version3.4

3 of 4

Bleomycin:

Renal impairment Hepatic impairment

CrCl >50 ml/min 100% doseCrCl 10-50 ml/min 25% dose reduction

CrCl 51 micromol/L & normal ALT/AST 50% dosereductionBilirubin >51 micromol/L & ALT/ AST >180 u/L omit

Neuropathy - in the presence of motor weakness or severe sensory symptoms, discuss reducingor withholding vinblastine with a consultant.

Dacarbazine:Renal impairment - discuss with

consultantHepatic impairment

BOPA recommendations:CrCl >60 ml/min give 100% doseCrCl 46-60 ml/min give 80% doseCrCl 30-45 ml/min give 75% dose

CrCl

7/30/2019 abvd

4/4

Lymphoma group

This is a controlled document and therefore must not be changed or photocopiedABVD Authorised by Lymphoma lead

Dr. Chris Hatton

Date: August 2012

Published: September 2008Reviewed: May 2010

Amended: June 2011May & Aug 2012

Review: June 2013

Version3.4

4 of 4

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

Reactions to bleomycin are common and may present with shortness of breath, cough or 'flu

like' symptoms. The presentation may mimic the underlying present condition. If bleomycinlung is suspected, high resolution CT scanning of the chest, PFTs, measurement of arterial O2

saturation should be performed and the bleomycin discontinued. Alteration in liver functiontests and a transient rise in the LDH may occur. Consider use of antibiotics and systemicsteroids (see bleomycin supportive care policy).

Anaphylaxis can occur very rarely following administration of Dacarbazine.

Photosensitivity reactions may occur rarely.

Cardiotoxicity - monitor cardiac function. Doxorubicin may be stopped in future cycles if signsof cardiotoxicity, e.g. cardiac arrhythmias, pericardial effusion, tachycardia with fatigue.

ABVD is considered low risk for infertility.

REFERENCES

1. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin'sdisease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607-14.

2. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP,Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial(ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatmentof advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial(ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18.

3. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions orgrowth factors. Ann Oncol. 2007 Feb;18(2):376-80.

4. Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C,Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI. G-CSF is not necessary to maintain over

99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellentoutcomes in a 10-year analysis. Br J Haematol. 2007 Jun;137(6):545-52.

5. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR,Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group;Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stageHodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408.

6. UCLH - Dosage Adjustment for Cytotoxics in Hepatic Impairment (Version 3 - updated January 2009).

7. UCLH - Dosage Adjustment for Cytotoxics in Renal Impairment (Version 3 - updated January 2009).